Anna Flávia Matos Soares

Anna Flávia Matos Soares

Auto-generated profile, based on publicly available information

Anna Flávia Matos Soares

Laboratório de Controle de Qualidade - Programa de Pós-graduação em Ciências Farmacêuticas-CiPharma, Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto. Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2020 in Current Drug Research Reviews
Verified
Journal Article
Open access
PDF file
LCLara Maria Lopes de Castro
Lara Maria Lopes de Castro
JSJacqueline de Souza
Jacqueline de Souza
TCTamires Guedes Caldeira
Tamires Guedes Caldeira
BMBruna de Carvalho Mapa
Bruna de Carvalho Mapa
ASAnna Flávia Matos Soares
Anna Flávia Matos Soares
NSNeila Marcia Silva-Barcellos
Neila Marcia Silva-Barcellos
Background: Solubility, intestinal permeability and dissolution are the main factors that govern the rate and extent of drugs absorption and are directly related to bioavailability. Biopharmaceutics Classification System (BCS) is an important tool which uses in vitro results for comparison with bioavailability in vivo (biowaiver). Valsartan is widely used in the treatment of hypertension and shows different BCS classification in the literature (BCS class II or III). Objective: This work proposes the study of valsartan biopharmaceutics properties and its BCS classification. Methods: High Performance Liquid Chromatography (HPLC) method was developed and validated to quantify the drug in buffers pH 1.2, 4.5 and 6.8 respectively. Valsartan solubility was determined in these three different media using shake flask method and intrinsic dissolution rate. Evaluation of dissolution profile from coated tablets was conducted. Results: The low solubility (pH 1.2 and 4.5) and high solubility (pH 6.8) were observed for both solubility methods. Permeability data reported from the literature showed that valsartan is a low permeability drug. Valsartan presented the rapid release profile only in pH 6.8. Conclusion: We defined that valsartan is a class IV drug, in disagreement with what has been published so far. It is important to emphasize that the conditions considered here are indicated to define the biopharmaceutics classification by regulatory agencies.